की कीमत क्या है EQRx, Inc. (EQRX)

का मूल्य EQRx, Inc. (EQRX) है $2.34

का बाजार पूंजीकरण क्या है EQRx, Inc. (EQRX)

का बाजार पूंजीकरण EQRx, Inc. (EQRX) है $728.90M

EQRx, Inc. (EQRX) कमाई

EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.

वर्ष	कमाई	परिवर्तन
प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।

वर्ष

कमाई

परिवर्तन

प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।

कंपनी	कमाई	कमाई में अंतर	देश
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$-4.02B	-	AU
Moderna, Inc. MRNA.US	$-3.09B	-	US
Lonza Group AG LONN.SW	-	-	CH

कंपनी

कमाई

कमाई में अंतर

देश